Skip to main content
Equibles
KROS logo

KROS · Keros Therapeutics, Inc. · Documents

Track KROS — free

Use KROS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KROS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.08 +0.54 (+5.66%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Market Cap
$197.81M
Shares
19.62M
Volume · Nov 12 630.16K Avg daily vol (3M) 187.94K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $243.86M 10-K filed Mar 4, 2026 Quarterly report FY2026 Q3 Revenue $40.01M up 183.3% 10-Q filed Nov 5, 2026 Latest results Rinvatercept Phase 2 dosed; net income reached $14.2 million 8-K filed Nov 5, 2026
2026
Nov 5
Current report 8-K
Rinvatercept Phase 2 commenced; initial data expected first half of 2027

Keros Therapeutics commenced an open-label, multi-cohort Phase 2 basket clinical trial of rinvatercept in Duchenne muscular dystrophy and expects initial data in the first half of 2027.

Regulation FD disclosure
Source passage
We have commenced an open-label, multi-cohort Phase 2 basket clinical trial to evaluate rinvatercept in patients with DMD and we expect to report initial data from this trial in the first half of 2027 Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $40.01M ▲ 183.3% Net income $14.15M Diluted EPS $0.70
Nov 5
Current report 8-K
Rinvatercept Phase 2 dosed; net income reached $14.2 million

Keros Therapeutics reported $14.2 million net income for third quarter 2026; the first rinvatercept Phase 2 patient was dosed in September 2026. Cash was $259.5 million at September 30, 2026, with runway expected into the second half of 2028.

Financial results
3 source passages
Keros reported net income of $14.2 million in the third quarter of 2026 as compared to a net loss of $7.3 million in the third quarter of 2025. In September 2026, Keros announced the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with DMD. Keros’ cash and cash equivalents as of September 30, 2026 was $259.5 million compared to $287.4 million as of December 31, 2025. Based on current operating assumptions, Keros expects that its cash and cash equivalents as of September 30, 2026 will enable Keros to fund its operating expenses and capital expenditure requirements into the second half of 2028. Open the document at this passage
Sep 29
Current report 8-K
Regulation FD disclosure

Keros Therapeutics expects to receive a $20 million elritercept development milestone from Takeda after first-patient dosing in the Phase 3 ELRiSE MF trial and plans to distribute 25% of net cash proceeds to stockholders after receipt.

Sep 28
Current report 8-K
Regulation FD disclosure

Keros Therapeutics announced that the first patient was dosed in its Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy. Initial data are expected in the first half of 2027.

Sep 8
Current report 8-K
Other events AI summary on its way
Aug 3
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $0 Net loss $28.71M Diluted EPS -$1.45
May 14
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $32K ▼ 100.0% Net loss $23.71M Diluted EPS -$1.21
Apr 22
Proxy statement DEF 14A Meeting Jun 3, 2026
Proxy statement AI summary on its way
Mar 9
Current report 8-K
Other events AI summary on its way
Mar 4
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $243.86M Net income $87.01M Diluted EPS $2.30
2025
Showing 1–50 of 216 documents
Key facts CIK 1664710 CUSIP 492327101 13F (30d) 85 filings 70 filers Visit website Investor relations